GlassScriptPhysician profile
James J Omeara
NPI 1902872864
$2,610.93
in general payments reported to CMS, 2019-2025
25 companies · $272 in 2025
The $272 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $742 · 2020: $306 · 2021: $461 · 2022: $516 · 2023: $32.15 · 2024: $282 · 2025: $272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $586.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $585.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $415.05 | 2019-2022 | |
| Abiomed | $213.42 | 2019-2022 | |
| Boston Scientific Corporation | $205.40 | 2022-2024 | Watchman Flx |
| Novartis Pharmaceuticals Corporation | $192.76 | 2019-2025 | |
| Cardiovascular Systems INC. | $185.86 | 2019 | |
| Cook Medical LLC | $184.65 | 2019-2022 | |
| Penumbra, INC. | $156.85 | 2019-2021 | |
| Shockwave Medical, INC | $148.97 | 2021 | |
| Abbott Laboratories | $148.79 | 2019-2021 | |
| Bard Peripheral Vascular, INC. | $140.79 | 2021 | |
| Stryker Corporation | $133.90 | 2025 | Limflow System |
| Recor Medical INC | $112.05 | 2024 | Paradise Renal Denervation System |
| E.R. Squibb & Sons, L.L.C. | $92.50 | 2019-2024 | Camzyos |
| Livanova USA, INC. | $48.29 | 2022 | |
| Pfizer INC. | $42.10 | 2019-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.01 | 2019-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $35.40 | 2024 | Arcalyst |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $30.70 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $18.86 | 2025 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $17.81 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $17.43 | 2024 | Brilinta |
| Bardy Diagnostics, INC. | $15.00 | 2019 | |
| Inspire Medical Systems, INC. | $14.34 | 2023 | Inspire |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Omeara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.